(Q34954864)

5 August 2017

1 reference

title

Prognostic and predictive value of HER2/neu oncogene in breast cancer (English)

1 reference

5 August 2017

1 reference

1

Shahla Masood

1 reference

5 August 2017

Marilyn M Bui

2

1 reference

5 August 2017

publication date

1 October 2002

1 reference

Microscopy Research and Technique

5 August 2017

published in

1 reference

5 August 2017

volume

59

1 reference

5 August 2017

issue

2

1 reference

5 August 2017

page(s)

102-108

1 reference

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

c-erbB-2 oncoprotein expression in primary and advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Prognostic factors in breast cancer: use of cytologic preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJEMT.10181

21 January 2018

Identifiers

DOI

10.1002/JEMT.10181

1 reference

5 August 2017

1 reference